Tirzepatide demonstrates broad cardiometabolic benefits, improving cardiorenal health and heart failure outcomes

The tight link between hyperglycemia, adiposity, and cardiovascular disease (CVD) underscores the need for integrated cardiometabolic interventions. Traditional treatments often target individual risk factors, leaving a gap for comprehensive approaches. Obesity-related heart failure with preserved ejection fraction (HFpEF), in particular, lacks effective therapeutic options. Tirzepatide, a dual GIP and GLP-1 receptor agonist, is being explored for its potential to address these interconnected pathologies beyond its primary roles in type 2 diabetes and obesity.

This narrative review synthesized findings from key clinical development programs for Tirzepatide, including the SURPASS trials for type 2 diabetes, SURMOUNT trials for obesity, SURPASS-CVOT for cardiovascular outcomes, and SUMMIT for heart failure with preserved ejection fraction (HFpEF). The authors systematically summarized mechanistic rationale and clinical evidence on Tirzepatide's impact across the cardiovascular continuum, covering risk-factor modification, cardiorenal signals, and hard outcome data.

Across the SURPASS program, Tirzepatide produced large, dose-dependent reductions in HbA1c and substantial weight loss, consistently outperforming active comparators. In the SURMOUNT trials, marked and durable weight reduction was observed over long follow-up, accompanied by clinically relevant improvements in waist circumference, blood pressure, triglycerides, and inflammatory biomarkers. Exploratory analyses also suggested favorable effects on lipids, ambulatory blood pressure, and kidney-related endpoints. Tirzepatide also improved obstructive sleep apnea severity in adults with obesity. The SURPASS-CVOT trial demonstrated cardiovascular safety, showing noninferiority versus dulaglutide for 3-point major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD).

The SUMMIT trial showed reductions in worsening heart failure events and improvements in health status in obesity-related HFpEF, supporting a phenotype-specific role.